Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT00111787

Completed

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

Neoplasms, Breast
NCT01617668

Completed

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Breast Cancer
NCT00887575

Completed

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Breast Cancer
NCT00603408

Terminated

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Breast Cancer
NCT02637375

Withdrawn

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Breast Cancer
NCT00756470

Terminated

Phase II Neoadjuvant in Inflammatory Breast Cancer

Breast Cancer
NCT00003680

Unknown

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

Breast Cancer
NCT01528826

Unknown

Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial (NVBOX)

Breast Cancer
NCT01276769

Unknown

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT00251329

Unknown

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

Breast Cancer
NCT07116642

Recruiting

Comparing Patient Reported Outcomes and Clinical Outcomes Based on Different Scar Placement in Patients Undergoing Standard Breast Conserving Surgery for Breast Cancer: The PROM-S Study. (PROM-S)

Breast Cancer - Female | Surgery of Breast Cancer
NCT07024173

Recruiting

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer
NCT06906237

Recruiting

Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study (ScarABEO)

Breast Cancer | Oncoplastic Breast Surgery | Oncoplastic Breast-conserving Surgery | Chest Wall Perforator Flap
NCT06450314

Recruiting

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. (HEROES)

Metastatic Breast Cancer | HER2-positive Breast Cancer
NCT06123988

Recruiting

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer (FastER)

Advanced Breast Cancer | HER2-positive Breast Cancer
NCT05982093

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer
NCT05809024

Recruiting

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer | Hormone Receptor Positive，HER2-negative Breast Cancer
NCT05763992

Recruiting

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial (BREAKFAST-2)

Breast Cancer | Triple Negative Breast Cancer | Fasting | Dietary Exposure
NCT04715958

Recruiting

SHAPE Neoadjuvant Chemotherapy Response

Anatomic Stage III Breast Cancer AJCC v8 | Locally Advanced Breast Carcinoma
NCT04636710

Recruiting

Refining Local-Regional Therapy for IBC

Breast Cancer | Sentinel Lymph Node | Inflammatory Breast Cancer
NCT04468061

Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast Cancer | Triple Negative Breast Cancer | PD-L1 Negative
NCT01840293

Recruiting

Breast Cancer Proteomics and Molecular Heterogeneity

Primary Breast Cancer | Recurrent/Metastatic Breast Cancer
NCT05583110

Terminated

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)

HER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast Carcinoma
NCT05840211

Active, not recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer
NCT04352777

Completed

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer | Hormone Receptor Positive Tumor
NCT01349088

Withdrawn

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer
NCT02676986

Completed

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)

Primary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBN
NCT02730130

Completed

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

Breast Cancer | Metastatic Triple Negative
NCT03167619

Completed

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

Triple Negative Breast Cancer
NCT03789019

Completed

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

Metastatic Breast Cancer | Stage IV Breast Cancer
NCT02658708

Completed

Bright Light on Fatigue in Women Being Treated for Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer of Breast | Cancer of the Breast
NCT01007942

Completed

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

Metastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast Cancer
NCT00633464

Completed

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Locally Advanced Non-resectable Breast Cancer
NCT00100750

Completed

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma
NCT00003536

Withdrawn

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer
NCT00623233

Completed

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer
NCT07419971

Enrolling by invitation

Influencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer

Breast Reconstruction | Breast Cancer Females
NCT04290897

Completed

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8
NCT04090567

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8
NCT06369285

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer
NCT05301010

Completed

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic
NCT05301530

Completed

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic
NCT07268105

Withdrawn

Flange Fitting for NICU Pumping Parents to Explore Improved Milk Production and Satisfaction

Breast Pumping | Human Milk/Breastfeeding
NCT07281833

Recruiting

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment (CAPIcorn)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer
NCT04999917

Completed

Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer (BrIMA)

Breast Cancer | Breast Cancer Invasive | Breast Cancer in Situ
NCT04674306

Active, not recruiting

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

Residual Disease | TNBC - Triple-Negative Breast Cancer | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
NCT02654119

Completed

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

HER2 Positive Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7
NCT02015559

Completed

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Oral Complications | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer
NCT04297384

Completed

Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

Breast Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma
NCT06954831

Recruiting

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations